Fig. 2: Time to NLCB and overall survival. | Nature Medicine

Fig. 2: Time to NLCB and overall survival.

From: Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial

Fig. 2

a,b, Posterior survival curves (smooth) and Kaplan–Meier (stepped) estimates for the time to NLCB (a) and overall survival (b) in all patients (that is, biomarker-unselected or any biomarker subgroup combination), grouped by randomization. Tick marks on Kaplan–Meier curves denote censored patients. Weibull accelerated failure time models were used for survival estimates. Colored lines depict median posterior distribution, and shaded areas show 90% CrI. Insets: Patients at risk, cumulative events and estimated median survival times (in months) with 90% CrI.

Back to article page